Premier Alternatives

Hyku Biosciences

Drug Discovery · Burlington, MA · Founded 2021 · Privately Held (backing)

Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. Hyku Biosciences is based in Burlington, MA and was founded in 2021. It was valued at $85 million at its seed round in Nov 2024, the last priced event on record. It has raised $70.6 million across 2 recorded rounds; the latest was a $6.6 million debt round in Dec 2025.

PMV mark · valuation
$85.0M
Oct 2026
Priced at
its seed round
Nov 2024
Total raised
$70.6M
Last round
Debt
Dec 2025

Hyku Biosciences key facts

as of Oct 2026
  • Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently.
  • Hyku Biosciences is valued at approximately $85.0M as of Oct 2026, set at its seed round, Nov 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $70.6M across 2 recorded rounds; the latest was Debt ($6.6M) in Dec 2025.
  • Notable investors include RA Capital Management, KB Investment, Novartis Venture Fund, Chugai Venture Fund, Droia Ventures — 7 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$85.0M

Valued at $85.0M at its seed round, Nov 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Hyku Biosciences with a free account
  • ·Watch Hyku Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Hyku Biosciences funding rounds

2 rounds
Dec 2025Debt$6.6MSEC filing▮
Nov 2024Seed Round$64.0M▮
Full funding history →

Hyku Biosciences valuation

Hyku Biosciences was valued at $85 million at its seed round in Nov 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Hyku Biosciences raised?

Hyku Biosciences has raised $70.6 million across 2 recorded rounds since 2024. The largest was a $6.6 million debt round in Dec 2025.

Hyku Biosciences investors

7 investors are on record for Hyku Biosciences, including RA Capital Management, KB Investment, Novartis Venture Fund and Chugai Venture Fund. The debt round in Dec 2025 drew 8 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Indapta Therapeutics ($90 million), Sydnexis ($90 million) and Linnaeus Therapeutics ($83.1 million).

About Hyku Biosciences

Developer of small molecule therapeutics with novel mechanisms of action intended to inhibit proteins that drive disease progression potently. The company identifies compounds that covalently bind non-cysteine amino acids to facilitate the development of novel therapies that can address current challenges associated with many disease targets, including selectivity, druggability, and resistance, enabling patients to improve their lives by pushing the scientific boundaries of covalent medicines.

Industry
Drug Discovery
Sector
Healthcare
HQ
Burlington, MA, United States
Founded
2021
Employees
16
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.